https://www.selleckchem.com/pr....oducts/shin1-rz-2994
Until recently, step-up therapy in atopic dermatitis (AD) included primarily off-label use of phototherapy, systemic immunosuppressants and/or corticosteroids. These broadly impact the immune system and show efficacy across a gamut of inflammatory skin diseases, albeit with potential serious adverse-events. Recently, dupilumab was approved as the first biologic agent in AD and demonstrated better efficacy and safety than prior off-label therapies. This article is protected by copyright. All rights reserved.Interleukin (IL) - 17 in
Like
Comment
Share
